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Proteomics of cerebrospinal fluid for 
biomarker discovery in multiple sclerosis
The discovery of reliable biomarkers, which are eligible for the 
prediction of both disease progression and response to treatment, 
means a great challenge in the management of multiple sclerosis 
(MS), a devastating disease of the central nervous system. The results 
of recent proteomic findings from the cerebrospinal fluid of M S  
patients hold promise of finding ideal biomarkers in the near future.
by Dr J. Füvesi, Dr C. Rajda, Dr D. Zâdori, Dr K. Bencsik,
Prof. Dr L. Vécsei and Prof. Dr J. Bergquist
Multiple Sclerosis 
Multiple sclerosis is a dcmyclinative dis­
order of the central nervous system that 
affects mainly young adults. It has a great 
impact on quality of life, social and family 
life, and the careers of the patients.
In the majority of cases the disease starts 
with a relapsing-remitting (RR) phase. 
After a variable period of time it turns into 
a secondary progressive (SP) phase char­
acterized by the gradual accumulation of 
residual symptoms. In 10-15% of cases a 
continuous progression is observed from 
the very beginning, this is the primary pro­
gressive (PP) form. In very rare fulminant 
cases frequent relapses with incomplete 
remissions cause severe disability or even 
death in a short duration of time.
The diagnosis of multiple sclerosis is still 
mainly clinical, supported by MRI and 
cerebrospinal fluid (CSP) analysis find­
ings. 'Ihe revised McDonald Criteria |1) 
allow earlier diagnosis, especially in PP 
MS. The routine diagnostic CSP analysis 
in MS includes the detection of oligo­
clonal bands and quantitative IgC analy­
sis. Isoelectric focusing (IUP) on agarose 
gels followed by imniunoblotling is con­
sidered the ‘gold standard1 for detecting 
the presence of oligoclonal bands [2|. The 
sensitivity of the method is above 95% 
and the specificity is more than 86%. An 
increased IgG index and the presence of 
oligoclonal bands in the CSP support an 
MS diagnosis.
Although the diagnosis is quite straight­
forward in most cases, taking into account 
clinical findings and paraclinical tests, 
there are still no specific biomarkers to 
confirm the diagnosis nor do we have any-
validated prognostic markers to follow the 
progression of the disorder.
At the time of diagnosis, major problems 
include the identification of the different 
clinical forms of the disease and the iden­
tification of patients with a potential rapid 
progression before disability evolves; the 
differential diagnosis of clinically isolated 
syndrome (CIS) with optic neuritis as the 
presenting symptom, where neuromyelitis 
optica (NMO) spectrum disorder may be 
an alternative diagnosis. Markers of disease 
progression are needed to distinguish CIS 
patients with a high probability to develop 
clinically definite MS.
'Phere is also a need for biomarkers of 
response to treatment and biomarkers 
for better understanding the underlying 
pathological processes of the disease. 'Ibis 
is especially important with Ihe grow­
ing variety of treatment options; now it 
is possible to change therapy in the case 
of an inadequate treatment response and 
to escalate MS treatment to more aggres­
sive alternatives. In the near future indi­
vidualized treatment choices need better 
classification of patient characteristics.
In order to discover new biomarkers in 
MS, one should analyse the whole protein 
content of body- fluids, preferentially CSF. 
Because of its proximity to the central 
nervous system (CNS), CSF may reflect 
changes in the CNS that may help differen­
tiate normal and pathological conditions.
Proteomics
Proteomics is the study of protein expres­
sion in an organism. There are excellent 
reviews on proteomic approaches [3-5), so 
we will discuss here only certain aspects of
these methods relevant to multiple sclero­
sis biomarker research. Mass-spectrometry 
(jVf.S in Italic to distinguish from multi­
ple sclerosis in this paper) based protein 
identification strategies include whole- 
protein analysis (‘top-down’ proteomics) 
and analysis of enzymatically produced 
peptides (‘bottom-up’ proteomics) |4). 
The latter is the standard for large-scale or 
high-throughput analysis of highly com­
plex samples, and digestion with trypsin is 
the most common method. The separation 
of peptides and proteins is an important 
element of both approaches.
Mass spectrometry measures the mass-to- 
charge ratio (m/z) of ionized molecules, 
and, as multiple distinct peptides can have 
very similar or identical molecular masses, 
it can be difficult to identify the overlap­
ping peptides [3|. The use of separation 
techniques, therefore, reduces the cases of 
coincident peptide masses simultaneously 
introduced into the mass spectrometer. 
One of the most commonly used separa­
tion techniques is high-performance liquid 
chromatography (HPL.C) with a capillary 
column. Peptides of similar molecular 
mass but different hydrophobicity elute
The moss spectrometer: the advances within 
high resolution liquid chromatography ond 
Fourier tronslorm ion cyclotron resonance moss 
spectrometry hos lead to ground brooking 
protein discoveries in many biological os well 
as clinicol applications (Photo credit: Mikael 
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1 / 1 2013.04.14. 15:51
CLI-ONLINE Digital Magazine http://www.cli-online.com/fileadmin/templates/media/swf/emag/print....
The control ion trap: combining forefront 
technology with complex clinical samples is  the 
driving force for professor Bergquist's research 
group (Photo credit: Mikael Wallerstedt)
from the LC column and enter the mass 
spectrometer at different time points, no 
longer overlapping in the initial MS anal­
ysis. Liquid chromatography coupled to 
mass spectrometry reduces the complex­
ity of the sample and allows more precise 
protein identification.
In order to limit the risk of system­
atic errors and achieve a high sample 
throughput, labelling by means of iso­
baric tags for relative and absolute quan­
tification (iTRAQ) may be used (6). Mul­
tiple samples may be processed in parallel 
with this multiplexed approach. I he main 
advantage is that the samples are ana­
lysed under exactly the same condi­
tions. The relative abundance of labelled 
peptides indicates relative changes in 
protein expression.
LC-MS experiments generate an enor­
mous amount of data, making data analy­
sis one of the most challenging parts of 
protcomic analysis. Protein identification 
and quantification is achieved by database 
searching. Programs, such as Mascot etc., 
compare observed spectra to predicted 
spectra for candidate peptides from a pro­
tein database. In a recent study Schutzere/^/. 
established a database of the normal 
human CSF proleome (7).
Proleomics in multiple sclerosis 
In recent years a number of papers 
appeared describing protcomic analysis
of CSF or brain tissue of multiple scle­
rosis patients [8- 12]. The first papers in 
the field analysed pooled samples from a 
relatively small group of patients |8, 9], 
Hammack et al. |8] reported the analy­
sis of a pooled sample of three relaps­
ing-remitting MS patients and a pooled 
sample of three patients with non-MS 
inflammatory CNS disorders using two­
dimensional gel electrophoresis (2-DF.) 
and peptide mass fingerprinting. They 
identified four proteins in the gels con­
taining MS CSP that were not reported 
previously in normal human CSP: 
CRTAC-lB (cartilage acidic protein), 
tetranectin (a plasminogen-binding 
protein), SPARC-like protein (a calcium 
binding cell signalling glycoprotein) 
and autotaxin t (a phosphodiesterase).
In the study of Dumont et al. |9] CSF sam­
ples from five MS patients (4 RR, one SP) 
were analysed by 2-DE followed by liquid 
chromatography tandem mass spectrom­
etry. With this method 15 proteins have 
been identified that were not previously 
observed in non-multiple sclerosis CSP 
2-DE gels. These proteins were: psoriasin, 
calmodulin-related protein NB-l,annexin 
l, EWI-2, Nicmann-Pick disease type C2 
protein (NPC-2), semenogelin 1 (SEMI), 
semcnogelin 2 (SEM2), complement fac­
tor H-rclated protein 1 (FHR-1), pro­
collagen C-proteinase enhancer protein 
(PCPE), aldolase A, N-acctyllactosaminide 
(5- 1,3-Af-acctylglucosaminyI-transferase, 
tetranectin, cystalin A, superoxide 
dismutasc 3 and glutathione peroxidase.
Later, publications started to focus on the 
differentiation of the clinical forms of the 
disease. Lchmensiek et al. compared CSF 
samples from RR MS and clinically iso­
lated syndrome (CIS) patients with con­
trols using two-dimensional difference gel 
electrophoresis (2-D-DIGE) and matrix- 
assisted laser desorption/ionization -  time 
of fiight (MALDI-TOF) mass spectrome­
try [ 10]. In RR MS Ig kappa chain NIG93 
protein was increased in concentration, 
while transferrin isoforms, alpha 1 antit­
rypsin isoforms, alpha 2-HS glycoprotein, 
Apo E and transthyretin decreased. In a 
study of Stoop et al. [II] significant differ­
ences were observed comparing the peak 
lists of spectra from CSF of MS patients 
and patients with other neurological dis­
eases (OND), and also clinically isolated 
syndrome (CIS) vs OND. Three differen­
tially expressed proteins were identified in 
the CSP of MS patients compared to CSF 
of patients with OND: chromogranin A, 
clustcrin and complement C3.
The same group compared proteoine 
profiles of CSF from RR and PP multiple 
sclerosis and found that they overlap to a 
large extent [13]. The main delected dif­
ference was that protein jagged-1 was less 
abundant in PP MS compared to RR MS, 
whereas vitamin D-binding protein was 
only detected in the RR MS CSP sam­
ples. Ottervald et al. found an increased 
CSF level of vitamin-D-binding protein 
in SP MS compared to the control |14). 
Recently, impaired vitamin D homeostasis 
has been linked to multiple sclerosis [15]: 
high scrum levels of 25-hydroxyvitamin 
D correlated with a reduced risk of MS 
[16] and vitamin D supplementation was 
proposed as an add-on therapy 117].
Biomarkers of disease progression arc 
emerging as new targets of proleomics. In 
our recently published paper we analysed 
the CSP of a rare fulminant case of MS 
and compared it with RR MS and control 
samples [ 18]. The aim of this study was to 
identify proteins related to rapid progres­
sion. The presented bottom-up strategy, 
based on isobaric lag labelling in conjunc­
tion with enzymatic digestion followed by 
nanoLC coupled off-line to MALDI TOF/ 
TOP MS resulted in the identification of 
78 proteins. Seven proteins were found to 
be upregutated in both fulminant MS sam­
ples but not in the relapsing-remitting case 
compared to the control. These proteins 
included Ig kappa and gamma-1 chain C 
region, complement C4-A, fibrinogen beta 
chain, serum amyloid A protein, neural cell 
adhesion molecule 1 and beta-2-glycopro­
tein 1. These proteins are involved in the 
immune response, blood coagulation, cell 
proliferation and cell adhesion.
"The search for biomarkers that 
are able to identify patients at 
high risk of rapid progression 
becomes increasingly 
important with the appearance 
of more aggressive 
treatment possibilities."
Disease progression may be examined by 
analysing CSF samples from CIS patients 
who remain CIS and CIS patients who 
convert to clinically definite multi­
ple sclerosis. Comabclla et al. [19, 20] 
analysed pooled CSP samples with 
isobaric labelling and mass spectrometry.
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'they found lhal chitinase 3-like 1, ceru­
loplasmin and vitamin D-binding protein 
were upregulaled in CSF of patients con­
verted to clinically definite MS. In order 
to validate their results, the authors deter 
mined the levels of these selected proteins 
by enzyme-linked immunosorbent assay 
(ELISA) in individual CSF samples. Only 
chitinase 3-like I was validated. In a sec 
ond validation step CSF chitinase 3-like 1 
levels were measured in an independent 
CIS cohort and its level was again signifi 
cantly increased in CIS patients who later 
converted to MS, compared to patients 
who remained as CIS. High CSF levels 
of this protein significantly correlated 
with the number of gadolinium enhanc­
ing and T2 lesions on baseline brain 
MRI scans and disability progression 
during follow up.
The search for biomarkers that are 
able to identify patients at high risk of 
rapid progression becomes increasingly 
important with the appearance of more 
aggressive treatment possibilities. In 
another ongoing study we currently ana 
lyse LC-Fourier transform ion cyclotron 
resonance (FTICR) MS 120 22] data 
of a larger set of CSF samples from a 
variety of clinical forms of MS and 
matched controls.
Despite the increasing number of studies 
investigating potential biomarkers of MS 
disease progression and response to ther 
apy, there is still no protein that is repeat­
edly identified and validated by different 
groups. This may be due to the relatively 
small sample sizes and the heterogeneity 
of the methods applied. Urge scale multi­
centre projects using standard methods 
for collecting, storing and analysing the 
samples are necessary to validate these 
preliminary results and integrate candidate 
biomarkers into the palhomechanism of 
the disease.
A great step in this direction is the 
BIOMS project, which aims a standard 
ized sample collection, storage and pro 
cessing during the preanalytical steps to 
rule out the differences occurred by sam­
ple preparation 123-25) and test the dif­
ferent methods and hypotheses on a great 
sample number in multiple centres to 
shed light on the sources of errors using 
different methods. One of these inilia 
tives was the neurofilament validation 
study, which is a candidate biomarker in 
multiple sclerosis [26). Another valida­
tion study tested two different methods 
of detecting the neutralizing antibodies
against interferon-beta therapy, which is 
a biomarker of therapy in MS (27|.
In the future multi-centre studies on 
standardized samples and methods can 
bring us closer to solve the questions 
regarding the pathological processes and 
the classification of patients to the most 
appropriate therapy.
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